# An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer

> **NCT05030493** · — · ACTIVE_NOT_RECRUITING · sponsor: **Takeda** · enrollment: 787 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** mFOLFOX6 + panitumumab combination therapy
- **DRUG:** mFOLFOX6 + bevacizumab combination therapy

## Key facts

- **NCT ID:** NCT05030493
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-31
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 787 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05030493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05030493, "An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05030493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*